BeOne Medicines
Aeschengraben 27, 21st Floor, Basel, Basel-Stadt, 4051, Switzerland
Overview
BeOne Medicines is a global oncology biotechnology company focused on discovering, developing, manufacturing, and commercializing cancer medicines. It offers approved therapies such as BRUKINSA (zanubrutinib) for hematologic malignancies and TEVIMBRA (tislelizumab) for solid tumors, alongside a broad pipeline of investigational agents including sonrotoclax, BGB-16673, and antibody-drug conjugates. BeOne conducts late-stage clinical trials across blood and solid cancers, operates biologics manufacturing facilities, and runs patient support, expanded access, and clinical trial programs. The company engages in global partnerships and access initiatives to expand availability of its oncology treatments.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 1
Sector focus
- Biopharma
- Biotechnology
- Clinical Trials
- Health Care
- Manufacturing
- Oncology
- Personal Health
- Pharmaceutical
Investment portfolio
- Terremoto Biosciences
Participated · Series C · Apr 2026
Terremoto Biosciences is a clinical-stage biotech company focused on designing highly selective, potent small-molecule AKT1 inhibitors. Its lead oncology program, TER-2013, is in Phase 1 clinical development for solid tumors harboring PIK3CA, AKT, or PTEN alterations. The company is also advancing TER-4480 for hereditary hemorrhagic telangiectasia, with clinical entry expected later this year. Terremoto emphasizes AKT1 selectivity to maximize efficacy while minimizing toxicities associated with AKT2 or PI3Kα inhibition. It is privately held and supported by investors including OrbiMed, Third Rock Ventures, Novo Holdings, Cormorant Asset Management, RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines. Terremoto is based in South San Francisco and San Diego.
Team
Niyoshi P. Patel
Senior Director, Business Development & Investments
LinkedIn